Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma

International Journal of Cancer

Volumn 127, Issue 1, 2010, Pages 67-76

  Shapovalov, Yuriy ^a   Benavidez, David ^a   Zuch, Daniel ^a   Eliseev, Roman A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Apoptosis; Bortezomib; Osteosarcoma; Proteasome inhibition; Runx2

Indexed keywords

BORTEZOMIB; PROTEASOME; PROTEIN BAX; TRANSCRIPTION FACTOR RUNX2; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PRIMER DNA; PYRAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE TUMOR; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG INHIBITION; ENZYME INHIBITION; FETUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTRATIBIAL TUMOR; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIBIA; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BORONIC ACIDS; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; OSTEOSARCOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 77953364958     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25024     Document Type: Article

References (39)

1. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-89.
2. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthopaed Relat Res 2002;397:40.
3. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma, The Oncologist 2004;9:422-41.
4. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32:423-36.
5. Bielack SS, Carrle D. State-of-the-art approach in selective curable tumors: bone sarcoma. Ann Oncol 2008;19:vii155-60.
6. Dahlin DC, Unni KK. Bone tumors: general aspects and data on 8,542 casesed. IL: Thomas Springfield, 1986.
7. Hopyan S, Gokgoz N, Bell RS, Andrulis IL, Alman BA, Wunder JS. Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours. J Orthopaed Res 1999;17:633-8.
8. Kawakami T, Shimizu T, Kimura A, Hasegawa H, Siar CH, Ng KH, Nagatsuka H, Nagai N, Kanda H. Immunohistochemical examination of cytological differentiation in osteosarcomas. Eur J Med Res 2005;10:475.
9. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747.
10. Massagué J, Gomis RR. The logic of TGFß signaling. FEBS Lett 2006;580: 2811-20.
11. Okuda T, Van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML 1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996;84:321-30.
12. Komori T. Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab 2003;21:193-7.
13. Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kawaguchi S, Ogawa M, Bae SC. Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci 2002;5: 946-54.
14. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t (8; 21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene. AML1. Proc Natl Acad Sci USA 1991;88:10431-4.
15. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004; 167:925.
16. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
17. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-87.
18. Eliseev RA, Dong YF, Sampson E, Zuscik MJ, Schwarz EM, O'Keefe RJ, Rosier RN, Drissi MH. Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis. Oncogene 2008;27: 3605-14.
19. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2: 647-56.
20. Shen R, Chen M, Wang YJ, Kaneki H, Xing L, O'Keefe RJ, Chen D. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J Biol Chem 2006;281: 3569.
21. Shen R, Wang X, Drissi H, Liu F, O'Keefe RJ, Chen D. Cyclin D1-cdk4 induce runx2 ubiquitination and degradation. J Biol Chem 2006;281:16347.
22. Jones DC, Wein MN, Oukka M, Hofstaetter JG, Glimcher MJ, Glimcher LH. Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3, Science 2006;312:1223-7.
23. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S. Pharmacologic targeting of a stem/ progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Investig 2008;118:491-504. (Pubitemid 351206540)
24. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334.
25. Nicholson DW. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 1999;6:1028-42.
26. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005;22:319-29.
27. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo, Cancer Research 2000;60: 5165-70.
28. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DPM. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008;14:2962.
29. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. CA Cancer J Clin 2008;112: 2119-29.
30. Harris SA, Enger RJ, Riggs BL, Spelsberg TC. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res 1995;10:178.
31. Nathan SS, Pereira BP, Zhou Y, Gupta A, Dombrowski C, Soong R, Pho RWH, Stein GS, Salto-Tellez M, Cool SM. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 2009;36:153-8.
32. Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A, Komori T, Nakatsuka M. Cbfa1 isoforms exert functional differences in osteoblast differentiation. J Biol Chem 1999;274: 6972-8.
33. Attar EC, DeAngelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res 2008;14:1446.
34. Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007;67: 1735.
35. Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol 2007;81: 10029.
36. Bae SC, Lee YH. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 2006;366:58-66.
37. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease, Cancer Research 2004;64:4506-13.
38. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003;56:13-22. (Pubitemid 36613151)
39. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 2009;100:24-8.